Vertex Announces US FDA Approval for Expanded Use of CASGEVY® for the Treatment of People Ages 2 Years and Older With Sickle Cell Disease or Transfusion-Dependent Beta Thalassemia
Go back to Vertex Announces US FDA Approval for Expanded Use of CASGEVY® for the Treatment of People Ages 2 Years and Older With Sickle Cell Disease or Transfusion-Dependent Beta Thalassemia| Vertex Pharmaceuticals Inc (NASDAQ: VRTX) | Delayed: 508.34 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $508.34 | 52 Week High | $134.71 | |||
| Open | $508.34 | 52 Week Low | $73.31 | |||
| Day High | $508.34 | P/E | N/A | |||
| Day Low | $508.34 | EPS | $-1.98 | |||
| Volume | 919 | |||||
